Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis
Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn:
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Chandler, Arizona 85224, United States
Peoria, Arizona 85381, United States
Tucson, Arizona 85712, United States
Glen Burnie, Maryland 21061, United States
Fayetteville, North Carolina 28304, United States
San Antonio, Texas 78229, United States
Adelaide, South Australia 5042, Australia
Bogotá, Cundinamarca 110111, Colombia
Nice, Alpes-Maritimes 06202, France
Pessac, Aquitaine 33600, France
Lyon, Auvergne-Rhône-Alpes 69004, France
Limoges, Limousin 87042, France
Santander, Cantabria 39005, Spain
Valladolid, Castille and León 47010, Spain
A Coruña, La Coruna 15006, Spain
Barcelona, 08035, Spain
Seville, 41013, Spain
Bangkok, Bangkok 10700, Thailand